Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation

Leukemia

Volumn 17, Issue 8, 2003, Pages 1643-1649

  Piovan, E ^a   Bonaldi, L ^a,b   Indraccolo, S ^a,c   Tosello, V ^a   Menin, C ^a,c   Comacchio, F ^a   Chieco Bianchi, L ^a   Amadori, A ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c IST Viral/Molecular Oncology Section   (Italy)

Author keywords

BZLF 1; EBV; FISH; Lymphoma; SCID mice

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; B LYMPHOCYTE; CARCINOGENESIS; CELL POPULATION; CELL TRANSFORMATION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYMPHOMA CELL; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SCID MOUSE; SEX DIFFERENCE; STATISTICAL ANALYSIS; TRANSCRIPTION INITIATION; TUMOR GROWTH; VIRUS INFECTION; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EID: 0041853566     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403005     Document Type: Article

References (34)

1. Rickinson AB, Kieff E. Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM (eds). Fields Virology, 4th edn, Vol. 2. Philadelphia: Lippincott-Raven Publishers, 2001, pp 2511-2627.
2. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994; 68: 7374-7385.
3. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15: 405-431.
4. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev 1995; 59: 387-405.
5. Rickinson AB, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996; 8: 492-497.
6. + T-cell response to Epstein-Barr virus: T-cell-mediated activation of resting B cells and induction of viral BZLF1 expression. J Virol 2000; 74: 6675-6679.
7. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature (London) 1983; 301: 527-530.
8. Custer RP, Bosma GC, Bosma MJ. Severe combined immunodeficiency (SCID) in the mouse. Pathology, reconstitution and neoplasms. Am J Pathol 1985; 120: 464-477.
9. Mosier DE, Gulizia RJ, Baird SM, Wilson DB. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (London) 1988; 335: 256-259.
10. Veronese ML, Veronesi A, D'Andrea E, Del Mistro A, Indraccolo S, Mazza MR et al. Lymphoproliferative disease in Human peripheral blood mononunclear cell-injected SCID mice. T lymphocyte requirement for B cell tumor generation. J Exp Med 1992; 176: 1763-1767.
11. Johannesen M, Asghar M, Crawford DH. Essential role for T cells in human B-cell lymphoproliferative disease development in severe combined immunodeficient mice. Br J Haematol 2000; 109: 600-610.
12. Hussel T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-574.
13. Miyashita. EM, Yang B, Lam KMC, Crawford DH, Thorley-Lawson DA. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 1995; 80: 593-601.
14. Thiele DL, Kurosaka M, Lipsk PE. Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol 1983; 131: 2282-2290.
15. Coppola V, Veronesi A, Indraccolo S, Calderazzo F, Mion M, Minuzzo S et al. Lymphoproliferative disease in human peripheral blood mononuclear cell-injected SCID mice. IV. Differential activation of human Th-1 and Th-2 lymphocytes and influence of the atopic status on lymphoma development. J Immunol 1998; 160: 2514-2522.
16. Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA et al. Genetic control of the CD4/CD8 T cell ratio in humans. Nat Med 1995; 1: 1279-1283.
17. Tosato G, Pike SE, Koski IR, Blaese RM. Selective inhibition of immunoregulatory cell functions by cyclosporin A. J Immunol 1982; 128: 1986-1991.
18. Pinkel D, Straume T, Gray JW. Cytogenetic analysis using quantitative, high sensitivity, fluorescence hybridization. Proc Natl Acad Sci USA 1986; 83: 2934-2938.
19. Polack A, Hartl G, Zimber U, Freese UK, Laux G, Takaki K et al. A complete set of overlapping cosmid clones of M-ABA virus derived from nasopharyngeal carcinoma and its similarity to other Epstein-Barr virus isolates. Gene 1984; 27: 279-288.
20. Alfarano A, Indraccolo S, Circosta P, Minuzzo S, Vallario A, Zamarchi R et al. An alternatively spliced form of CD79b gene may acount for altered B-cell receptor expression in B-chronic lymphocytic leukemia. Blood 1999; 93: 2327-2335.
21. 1 gene transfer on in vivo growth of human breast cancer cells. Gene Therapy 2002; 9: 867-878.
22. Santini SM, Rizza P, Logozzi MA, Sestili P, Gherardi G, Lande R et al. The SCID mouse reaction to human peripheral blood mononuclear leukocyte engraftment. Transplantation 1995; 60: 1306-1314.
23. Fukuda M, Satoh TA, Takanashi M, Hirai K, Ohnishi E, Sairenji T. Inhibition of cell growth and Epstein-Barr virus reactivation by CD40 stimulation in Epstein-Barr virus-transformed B cells. Viral Immunol 2000; 13: 215-229.
24. Rowe M, Young LS, Crocker J, Stokes S, Henderson S, Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991; 173: 147-158.
25. Schimke RT, Hill A, Johnston RN. Fifth Gordon Hamilton-Farley memorial lecture. Methotrexate resistance and gene amplification: an experimental model for the generation of cellular heterogeneity. Br J Cancer 1985; 51: 459-465.
26. Larkins BA, Dilkes BP, Dante RA, Coelho CM, Woo YM, Liu Y. Investigating the hows and whys of DNA endoreduplication. J Exp Bot 2001; 52: 183-192.
27. Armitage JM, Kormos RL, Stuart RS, Fricker FJ, Griffith BP, Nalesnik M et al. Post transplant lymphoproliferative disease in thoracic organ transplant patients: Ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877-887.
28. Knowles DM, Cesarmen E, Chadburn A, Frizzera G, Chen J, Rose EA et al. Correlative morphologic and genetic analysis demonstrates three distinct categories of post-transplantation lymphoproliferative disorders. Blood 1995; 85: 552-565.
29. Barrett JC. Posttransplantation lymphoproliferative disease. HERPES 2000; 7: 4-8.
30. Amadori A, Veronesi A, Coppola V, Indraccolo S, Mion M, Chieco-Bianchi L. The hu-PBL-SCID mouse in human lymphocyte function and lymphomagenesis studies: achievements and caveats. Semin Immunol 1996; 8: 249-254.
31. Srivastava T, Zwick DL, Rothberg PG, Warady BA. Posttransplant lymphoproliferative disorder in pediatric renal transplantation. Pediatr Nephrol 1999; 13: 748-754.
32. Birkeland SA, Andersen HK, Hamilton-Dutoit SJ. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol. Transplantation 1999; 67: 1209-1214.
33. Westphal EA, Blackstock W, Feng W, Israel B, Kenney SC. Activation of lytic Epstein-Barr virus (EBV) infection by radiation and sodium butyrate in Vitro and in Vivo: a potential method for treating EBV-positive malignancies. Cancer Res 2000; 60: 5781-5788.
34. Murphy WJ, Funakoshi S, Beckwith M, Rushing SE, Conley DK, Armitage RJ et al. Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes. Blood 1995; 86: 1946-1953.